Clinical trials: CINV
Cancer
A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
This aim of study is to evaluate the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy by a randomized, double-blind…
- Trial name
- NCT02400866
- Testing
- Olanzapine
- Volunteers
- 58 people
- Sponsor
- Korean South West Oncology Group
Breast Cancer, Chronic Myeloproliferative Disorders
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00900068
- Testing
- immunoenzyme technique, laboratory biomarker analysis, medical chart review
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- OHSU Knight Cancer Institute
Pediatric Cancer, Chemotherapy-induced Nausea and Vomiting
Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients
Chemotherapy is a cancer therapy performed on advanced cancer with quite good success, but this therapy has quite a lot of side effects.
- Conditions
- Pediatric Cancer, Chemotherapy-induced Nausea and Vomiting, Chemotherapy Effect
- Trial name
- NCT05851625
- Testing
- Press needle acupuncture, Plesterin
- Where
- Indonesia
- Volunteers
- 64 people
- Sponsor
- Universitas Indonesia
Vomiting
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.
- Trial name
- NCT02576327
- Testing
- Tropisetron, Dexamethasone, Aprepitant
- Volunteers
- 130 people
- Sponsor
- Jun Zhu
Chemotherapy-Induced Nausea and Vomiting (CINV), Cancer
Geranium Inhalation Aromatherapy for Reducing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) remain among the most distressing side effects experienced by cancer patients and can significantly affect treatment tolerance and quality of life.
- Trial name
- NCT07292831
- Testing
- Geranium Inhalation Aromatherapy
- Where
- Indonesia
- Volunteers
- 90 people
- Sponsor
- Universitas Muhammadiyah Surakarta
Chemotherapy-induced Nausea and Vomiting
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic…
- Trial name
- NCT04054193
- Testing
- Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
- Where
- 26 sites in United States, Greece and 7 more
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea
The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children
In this pilot study, the Baxter Retching Faces (BARF) Scale will be used to assess chemotherapy induced nausea and vomiting (CINV) in the pediatric cancer population during chemotherapy admissions, and the corresponding…
- Trial name
- NCT04678947
- Testing
- Baxter Retching Faces (BARF) scale
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
This is a prospective, multicenter, open label, non-comparative trial in Spain. The primary objective of this study is to determine the complete response, defined as no vomiting and no use of rescue treatment, in women with…
- Trial name
- NCT01298193
- Testing
- Aprepitant
- Where
- 13 sites in Spain
- Volunteers
- 212 people
- Sponsor
- Spanish Breast Cancer Research Group
Chemotherapy-induced Nausea and Vomiting
Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV
Chemotherapy-induced nausea and vomiting is a common side effect of cancer treatments, and dexamethasone offers a clear advantage over placebo for protection against chemotherapy-induced emesis in both acute and delayed phases.
- Trial name
- NCT04437017
- Testing
- Olanzapine+NK-1 RA+5-HT3 RA, Dexamethasone+NK-1 RA+5-HT3 RA
- Where
- China
- Volunteers
- 557 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Breast Cancer, Malignant Female Reproductive System Neoplasm
Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting
This randomized controlled three arm study compares the effects of a yoga intervention with jacobsons progressive muscle relaxation training and only standard of care in chemotherapy naive cancer patients.
- Conditions
- Breast Cancer, Malignant Female Reproductive System Neoplasm, Lymphomas, Chemotherapy-induced Nausea and Vomiting
- Trial name
- NCT01387841
- Testing
- yoga, Jacobsons PMRT group
- Where
- India
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Bharath Charitable Cancer Hospital and Institute
Chemotherapy-induced Nausea and Vomiting
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (> 24-120…
- Trial name
- NCT02106494
- Testing
- APF530, Ondansetron, Fosaprepitant
- Where
- 7 sites in United States
- Volunteers
- 942 people
- Sponsor
- Heron Therapeutics
Myeloma, Plasma-Cell, Lymphoma, Malignant
Multi-day Doses in Prevention of Nausea and Emesis
To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational…
- Trial name
- NCT00600353
- Testing
- Palonosetron, Aprepitant, Dexamethasone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Chemotherapy-induced Nausea and Vomiting
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
This prospective, multicenter, non-comparative, open-label trial design aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by…
- Trial name
- NCT07482891
- Testing
- Fosrolapitant and Palonosetron Hydrochloride for Injection, Dexamethasone, Olanzapine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai 6th People's Hospital
Chemotherapy-Induced Nausea and Vomiting (CINV)
QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration
This is a single-center, single-dose, randomized, open-label, crossover study. Forty-two healthy male and female participants will be enrolled.
- Trial name
- NCT07817004
- Testing
- apripitant and palonosetron injectable emulsion, palonosetron hydrochloride injection, apripitant injection (CINVANTI)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Chemotherapy-induced Nausea and Vomiting
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving HEC.
- Trial name
- HEC (NCT01500213)
- Testing
- Rolapitant, Granisetron, Dexamethasone
- Where
- United States
- Volunteers
- 555 people
- Sponsor
- Tesaro, Inc.
Malignant Neoplasm
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
This randomized phase III trial studies how well olanzapine with or without fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting.
- Trial name
- NCT03578081
- Testing
- Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone
- Where
- 566 sites in United States, Guam
- Volunteers
- 690 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
Transdermal granisetron has been shown to as effective as oral/ intravenous granisetron when administered with or without dexamethasone.
- Trial name
- NCT04912271
- Testing
- Granisetron transdermal patch, Palonosetron, Aprepitant
- Volunteers
- 140 people
- Sponsor
- Fudan University
Oncology
Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients
This pragmatic trial addresses the clinical gap through the generation of evidence on the comparative effectiveness between AKYNZEO® and Standard of Care (SoC, including EMEND®) in the real-life setting
- Trial name
- NCT03831633
- Testing
- Akynzeo, Standard of Care
- Where
- France
- Volunteers
- 426 people
- Sponsor
- VIFORFRANCE
Chemotherapy-induced Nausea and Vomiting (CINV)
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
This study is Phase 2 pharmacokinetic (PK) and pharmacodynamic (PD) dose-finding study of oral netupitant administered concomitantly with oral palonosetron in pediatric cancer patients for the prevention of nausea and vomiting…
- Trial name
- CINV (NCT03204279)
- Testing
- Netupitant, Palonosetron
- Where
- 17 sites in United States, Russia and 2 more
- Volunteers
- 67 people
- Sponsor
- Helsinn Healthcare SA